Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma

• Published in: Archives of Dermatological Research Vol. 306; no. 8; pp. 757 - 761
• Main Authors: Usategui, Alicia, Criado, Gabriel, Del Rey, Manuel J., Faré, Regina, Pablos, José L.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2014; Springer Nature B.V
• Subjects: Administration, Topical; Animals; Bleomycin - administration & dosage; Calcitriol - administration & dosage; Calcitriol - analogs & derivatives; Collagen - metabolism; Concise Communication; Cytokines - genetics; Cytokines - metabolism; Dermatologic Agents - administration & dosage; Dermatology; Disease Models, Animal; Female; Fibrosis; Humans; Hydroxyproline - metabolism; Interleukin-13 - genetics; Interleukin-13 - metabolism; Medicine; Medicine & Public Health; Mice; Mice, Inbred C3H; Scleroderma, Systemic - drug therapy; Scleroderma, Systemic - pathology; Skin - drug effects; Skin - pathology; Up-Regulation; IL-13; Vitamin D; TSLP; Systemic sclerosis

Vitamin D analogues can reduce TGF-β pro-fibrotic signaling in dermal fibroblasts, but they may also induce a potentially pro-fibrotic thymic stromal lymphopoietin (TSLP)-dependent Th2 cytokine local response. We have analyzed the net effect of topical vitamin D analogue calcipotriol (CPT) on the cy...